Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer.

ABSTRACT:

Purpose

The addition of trastuzumab to adjuvant chemotherapy has improved the outcome of human epidermal growth-factor receptor 2 (HER2)-positive breast cancer. Uncertainty remains about the optimal timing of trastuzumab treatment. Therefore, we compared long-term outcome after concurrent versus sequential treatment, in a population-based setting, using data from the nationwide Netherlands Cancer Registry.

Methods

We identified 1843 women diagnosed in The Netherlands from January 1st 2005 until January 1st 2008 with primary, HER2-positive, T_1-4N_anyM₀ breast cancer who received adjuvant chemotherapy and trastuzumab. Kaplan-Meier survival estimates and Cox regression were used to compare recurrence-free survival (RFS) and overall survival (OS)

SUBMITTER: Dackus GMHE 

PROVIDER: S-EPMC7921067 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature